Study Group: Rituxan Prescribers: Hematologists (US)(?)
Council Members in this Study Group: 46
Request a survey with this Study Group
Leading Experts in this Study Group
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Staff Physician
Ironwood Cancer & Research Center
Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Brian Abbott, MDMedical Director of Hematology
Big Sky Oncology
Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...
Director of the Oupatient Hematology
THE NEW YORK-PRESBYTERIAN HOSPITAL
Michael Flamm, MD, PhD, is the Director of the Outpatient Hematology Clinic at the Columbia Presbyterian campus of the New York Presbyterian Hospital. He has expertise in the treatment of sickle cell anemia and paroxysmal nocturnal hemoglobinuria, and he also treats patients with hematologic malignancies...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Hematologists (US) | 1019 |
| Oncologists who Treat Hematologic Malignancies (US) | 881 |
| Oncologists (US) | 2247 |
| Physicians who Treat Mantle Cell and NHL (US) | 88 |
| Hematologists who Treat CLL (US) | 73 |
| Physicians who Treat Multiple Myeloma (US) | 171 |
| Multiple Myeloma Physicians | 189 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.
Velcade + classic Melphalan/ Prednisone (MP) is better than MP alone. No surprise
Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.
Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Owner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

